Dr. Kurtzman has more than 25 years of experience as an entrepreneur, board member, financier and operator. As Managing Director of Healthcare at Safeguard Scientifics (NYSE:SFE), Dr. Kurtzman leverages his medical expertise to empower businesses to enhance their products, expand their services, and identify strategic partnership opportunities. Dr. Kurtzman has realized value for companies through a series of successful IPOs, M&A and turnaround transactions—most recently Shire’s acquisition of Safeguard’s partner company Advanced BioHealing for $750 million, in cash; and Eli Lilly’s acquisition of Safeguard’s partner company Avid Radiopharmaceuticals for $300 million, up front, with an additional $500 million payout dependent upon the achievement of future regulatory and commercial milestones. Dr. Kurtzman’s previous experiences include leadership roles at BioAdvance, Pluvita Corporation, Genovo, Avigen, and Gilead Sciences. Presently, Dr. Kurtzman is a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches entrepreneurship in life sciences. In addition, he is also a member of the board at Safeguard’s partner companies Alverix, Crescendo Bioscience, Good Start Genetics, Prognos and PixelOptics.